Insider Selling: Aerie Pharmaceuticals Inc (AERI) CEO Sells 50,000 Shares of Stock

Aerie Pharmaceuticals Inc (NASDAQ:AERI) CEO Vicente Anido, Jr. sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, June 11th. The stock was sold at an average price of $62.01, for a total transaction of $3,100,500.00. Following the completion of the transaction, the chief executive officer now directly owns 176,320 shares of the company’s stock, valued at approximately $10,933,603.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Aerie Pharmaceuticals traded up $0.90, reaching $63.90, during trading hours on Thursday, Marketbeat reports. 6,665 shares of the company’s stock were exchanged, compared to its average volume of 355,562. The company has a market cap of $2.51 billion, a PE ratio of -18.99 and a beta of 0.94. The company has a current ratio of 13.57, a quick ratio of 13.53 and a debt-to-equity ratio of 0.52. Aerie Pharmaceuticals Inc has a fifty-two week low of $47.05 and a fifty-two week high of $66.60.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings results on Tuesday, May 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.04. equities analysts forecast that Aerie Pharmaceuticals Inc will post -3.75 earnings per share for the current year.

A number of equities analysts recently commented on AERI shares. ValuEngine downgraded shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 26th. Mizuho set a $87.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, March 29th. BidaskClub raised shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 5th. Cantor Fitzgerald set a $86.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, May 8th. Finally, Canaccord Genuity set a $86.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, June 5th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $76.50.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Summit Trail Advisors LLC grew its holdings in shares of Aerie Pharmaceuticals by 12.1% during the first quarter. Summit Trail Advisors LLC now owns 11,922 shares of the company’s stock valued at $440,000 after buying an additional 1,283 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Aerie Pharmaceuticals during the first quarter valued at $942,000. Handelsbanken Fonder AB grew its holdings in shares of Aerie Pharmaceuticals by 100.0% during the first quarter. Handelsbanken Fonder AB now owns 260,000 shares of the company’s stock valued at $14,105,000 after buying an additional 130,000 shares during the last quarter. Xact Kapitalforvaltning AB purchased a new stake in shares of Aerie Pharmaceuticals during the first quarter valued at $258,000. Finally, Royal Bank of Canada grew its holdings in shares of Aerie Pharmaceuticals by 8.3% during the first quarter. Royal Bank of Canada now owns 32,875 shares of the company’s stock valued at $1,784,000 after buying an additional 2,511 shares during the last quarter.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply